Wealthcare Advisory Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

Wealthcare Advisory Partners’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-2,951	Closed	-$250K	–	694
2022 Q3	$250K	Buy	2,951 +87	+3%	+$7.75K	0.01%	525
2022 Q2	$237K	Buy	+2,864	New	+$228K	0.01%	483
2021 Q2	–	Sell	-4	Closed	–	–	703
2021 Q1	$0	Buy	+4	New	+$327	﹤0.01%	2060
2020 Q2	–	Sell	-10	Closed	-$1K	–	430
2020 Q1	$1K	Buy	+10	New	+$862	﹤0.01%	1362

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Wealthcare Advisory Partners's BMRN Position: Q4 2022 in Review

Wealthcare Advisory Partners sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2022, closing a stake of 2,951 shares — an estimated $250K sold.

Wealthcare Advisory Partners first reported a position in BMRN in Q1 2020 and held it in 4 quarters. The position peaked at $250K in Q3 2022. 580 funds tracked by Wall St. Rank hold BMRN as of Q4 2022.

Wealthcare Advisory Partners reported no remaining BioMarin Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Wealthcare Advisory Partners sold 2,951 BioMarin Pharmaceuticals shares in Q4 2022, an estimated $250K.
Wealthcare Advisory Partners first reported a position in BioMarin Pharmaceuticals in Q1 2020 and held it in 4 quarters.
Wealthcare Advisory Partners's BioMarin Pharmaceuticals position peaked at $250K in Q3 2022.
580 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2022.

Based on Wealthcare Advisory Partners's 13F filing for Q4 2022, filed 13 Feb 2023.